journal article·2021-01-13

Subtherapeutic Photodynamic Treatment Facilitates Tumor Nanomedicine Delivery and Overcomes Desmoplasia

Marta Overchuk, Kara M. Harmatys, Shrey Sindhwani, Maneesha A. Rajora, Adam Koebel, Danielle M. Charron, Abdullah M. Syed, Juan Chen, Martin G. Pomper, Brian C. Wilson, Warren C. W. Chan, Gang Zheng

Nano Letters· Volume 21· Issue 1
Publisher page

Abstract

Limited tumor nanoparticle accumulation remains one of the main challenges in cancer nanomedicine. Here, we demonstrate that subtherapeutic photodynamic priming (PDP) enhances the accumulation of nanoparticles in subcutaneous murine prostate tumors ∼3-5-times without inducing cell death, vascular destruction, or tumor growth delay. We also found that PDP resulted in an ∼2-times decrease in tumor collagen content as well as a significant reduction of extracellular matrix density in the subendothelial zone. Enhanced nanoparticle accumulation combined with the reduced extravascular barriers improved therapeutic efficacy in the absence of off-target toxicity, wherein 5 mg/kg of Doxil with PDP was equally effective in delaying tumor growth as 15 mg/kg of Doxil. Overall, this study demonstrates the potential of PDP to enhance tumor nanomedicine accumulation and alleviate tumor desmoplasia without causing cell death or vascular destruction, highlighting the utility of PDP as a minimally invasive priming strategy that can improve therapeutic outcomes in desmoplastic tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Princess Margaret Cancer Centre, University Health Network, 101 College Street, PMCRT 5-354, Toronto, Ontario M5G 1L7, Canada

Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5G 1L7, Canada

Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario M5S 3M2, Canada

J. David Gladstone Institutes, San Francisco, California 94158, USA

Department of Radiology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States

Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada

Funding

Canadian Institutes of Health Research · Government of Canada · Canada Foundation for Innovation · Canada Research Chairs · Terry Fox Research Institute · Princess Margaret Cancer Foundation · Natural Sciences and Engineering Research Council of Canada

References (48)

Show source-provided references
1. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
2. 10.1016/S1040-8428(86)80023-310.1016/S1040-8428(86)80023-3 ↗
3. 10.1016/j.nantod.2019.02.00510.1016/j.nantod.2019.02.005 ↗
4. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
5. 10.1039/C1CS15233E10.1039/C1CS15233E ↗
6. 10.1038/nrc.2017.5110.1038/nrc.2017.51 ↗
7. 10.1038/nrc.2017.9310.1038/nrc.2017.93 ↗
8. 10.3389/fmolb.2019.0016010.3389/fmolb.2019.00160 ↗
9. 10.1016/j.ccr.2012.03.00210.1016/j.ccr.2012.03.002 ↗
10. 10.7150/thno.3999510.7150/thno.39995 ↗
11. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
12. 10.1021/acs.bioconjchem.6b0043710.1021/acs.bioconjchem.6b00437 ↗
13. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
14. 10.1016/j.biomaterials.2017.10.02410.1016/j.biomaterials.2017.10.024 ↗
15. 10.7150/thno.3720410.7150/thno.37204 ↗
16. 10.3390/cancers902001910.3390/cancers9020019 ↗
17. 10.1007/s10103-008-0539-110.1007/s10103-008-0539-1 ↗
18. 10.1093/jnci/90.12.88910.1093/jnci/90.12.889 ↗
19. Snyder J. W. · Cancer Res. · 2003 · 63 · 8126
20. 10.1158/0008-5472.CAN-17-170010.1158/0008-5472.CAN-17-1700 ↗
21. 10.1021/nn501134q10.1021/nn501134q ↗
22. 10.7150/thno.1526210.7150/thno.15262 ↗
23. 10.1158/1078-0432.CCR-05-167310.1158/1078-0432.CCR-05-1673 ↗
24. 10.1016/j.tranon.2014.04.01010.1016/j.tranon.2014.04.010 ↗
25. 10.1002/lsm.2268710.1002/lsm.22687 ↗
26. 10.1002/lsm.2306910.1002/lsm.23069 ↗
27. 10.1093/ejcts/ezr29410.1093/ejcts/ezr294 ↗
28. 10.1158/1535-7163.MCT-13-063310.1158/1535-7163.MCT-13-0633 ↗
29. 10.1021/nn305011p10.1021/nn305011p ↗
30. 10.1039/C5NR05552K10.1039/C5NR05552K ↗
31. 10.1021/acs.accounts.9b0027310.1021/acs.accounts.9b00273 ↗
32. 10.1142/S108842462030009810.1142/S1088424620300098 ↗
33. 10.1021/jacs.8b0107210.1021/jacs.8b01072 ↗
34. 10.1038/nnano.2015.31110.1038/nnano.2015.311 ↗
35. 10.1007/s00018-016-2401-010.1007/s00018-016-2401-0 ↗
36. 10.1158/1535-7163.MCT-19-079110.1158/1535-7163.MCT-19-0791 ↗
37. 10.1021/acs.nanolett.9b0085910.1021/acs.nanolett.9b00859 ↗
38. 10.1016/j.jconrel.2015.08.01710.1016/j.jconrel.2015.08.017 ↗
39. 10.1158/0008-5472.CAN-13-349410.1158/0008-5472.CAN-13-3494 ↗
40. 10.1111/php.1318110.1111/php.13181 ↗
41. 10.1021/acsnano.5b0107710.1021/acsnano.5b01077 ↗
42. 10.1021/nn502858b10.1021/nn502858b ↗
43. 10.1021/nn500299p10.1021/nn500299p ↗
44. Tannock I. F. · Clin. Cancer Res. · 2002 · 8 · 878
45. 10.1093/jnci/80.20.159910.1093/jnci/80.20.1599 ↗
46. 10.1136/gut.2010.22609210.1136/gut.2010.226092 ↗
47. 10.3390/cancers1012049510.3390/cancers10120495 ↗
48. 10.1111/1759-7714.1294710.1111/1759-7714.12947 ↗